Could Phaxan™ become the new drug of choice for intravenous anaesthesia, procedural and intensive care sedation.

Get the Flash Player to see this video.

 

Could Phaxan™ become the new drug of choice for intravenous anaesthesia, procedural and intensive care sedation.

The need for a for a new anaesthetic that is both safe and effective continues to grow significantly, with more than 80 million general anaesthesia procedures performed annually in the United States and Europe alone.

Since Drawbridge Pharmaceuticals was founded in 2011, it has been building a robust patent portfolio around its lead drug candidate, Phaxan™, for global use in anaesthesia and sedation. During AusBiotech 2014 PharmaVentures' Fintan Walton caught up with Drawbridge CEO, Anthony Filippis to find out why Phaxan has the potential to become the new gold standard drug of choice for intravenous anaesthesia.